Clinical Trial Update: A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial evaluating CDX-1140, a CD40 agonist, in combination with capecitabine, oxaliplatin (CAPOX), and pembrolizumab for biliary tract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• CDX-1140
• Eloxatin (oxaliplatin)
• KEYTRUDA (PEMBROLIZUMAB)
• Xeloda (capecitabine) (capecitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Biliary Cancer, Bile Duct Cancer | Phase 1, Phase 2 | Status: RECRUITING